James W Winkler

6461875, Oct 8, 2002

Oct 2, 1998

09/165926

David Bar-Or - Englewood CO
Edward Lau - Boulder CO
James V. Winkler - Denver CO

Ischemia Technologies, Inc. - Arvada CO

G01N 33536

436536, 436 86, 436518, 435 4, 435 79, 422 8205, 422 8209

The present invention relates to a rapid method for the detection of ischemic states and to a kit for use in such a method. Provided for is a rapid method of testing for the existence of and quantifying ischemia based upon method of detecting and quantifying the existence of an alteration of the serum protein albumin which occurs following an ischemic event; methods for detecting and quantifying this alteration include evaluating and quantifying the cobalt binding capacity of circulating blood, analysis and measurement of the ability of serum albumin to bind exogenous cobalt, detection and measurement of the presence of copper in a purified albumin sample and use of an immunological assay sepcific to the alterated form of serum albumin which occurs following an ischemic event. Also taught by the present invention is the use of the compound Asp-Ala-His-Lys-R, wherein R is any chemical group capable of being detected when bound to any compound capable of binding to the N-terminus of naturally occurring human albumin (including no additional chemical group), for detection and quantification of an ischemic event.

6492179, Dec 10, 2002

Oct 2, 1998

09/165581

David Bar-Or - Englewood CO
Edward Lau - Boulder CO
James V. Winkler - Denver CO

Ischemia Techologies, Inc. - Arvada CO

G01N 3320

436 74, 436 63, 436 73, 436 86, 436 87, 436 88, 436171, 436903, 436904, 436518, 435 4, 435 71, 422 55, 422 66, 422 8205, 422 8209, 422 56, 422 58

The present invention relates to a rapid method for the detection of ischemic states and to a kit for use in such a method. Provided for is a rapid method of testing for the existence of and quantifying ischemia based upon method of detecting and quantifying the existence of an alteration of the serum protein albumin which occurs following an ischemic event; methods for detecting and quantifying this alteration include evaluating and quantifying the cobalt binding capacity of circulating blood, analysis and measurement of the ability of serum albumin to bind exogenous cobalt, detection and measurement of the presence of copper in a purified albumin sample and use of an immunological assay sepcific to the alterated form of serum albumin which occurs following an ischemic event. Also taught by the present invention is the use of the compound Asp-Ala-His-Lys-R, wherein R is any chemical group capable of being detected when bound to any compound capable of binding to the N-terminus of naturally occurring human albumin (including no additional chemical group), for detection and quantification of an ischemic event.

7282369, Oct 16, 2007

Apr 15, 2003

10/414469

David Bar-Or - Englewood CO, US
Edward Lau - Boulder CO, US
James V Winkler - Denver CO, US

Ischemia Technologies, Inc. - Waltham MA

G01N 33/20
G01N 33/48
G01N 31/00

436 74, 436 17, 436 63

The present invention relates to rapid methods for the detection of ischemic states and to kits for use in such methods. Provided for is a rapid method of testing for and quantifying ischemia based upon methods of detecting and quantifying the existence of an alteration of the serum protein albumin which occurs following an ischemic event; methods for detecting and quantifying this alteration include evaluating and quantifying the cobalt binding capacity of circulating albumin, analysis and measurement of the ability of serum albumin to bind exogenous cobalt, detection and measurement of the presence of endogenous copper in a purified albumin sample and use of an immunological assay specific to the altered form of serum albumin which occurs following an ischemic event. Also taught by the present invention is the detection and measurement of an ischemic event by measuring albumin N-terminal derivatives that arise following an ischemic event, including truncated albumin species lacking one to four N-terminal amino acids or albumin with an acetylated N-terminal Asp residue.

7297544, Nov 20, 2007

Apr 15, 2003

10/413831

David Bar-Or - Englewood CO, US
Edward Lau - Boulder CO, US
James V. Winkler - Denver CO, US

Ischemia Technologies, Inc. - Waltham MA

G01N 33/53

436 71, 436518, 436536

The present invention relates to rapid methods for the detection of ischemic states and to kits for use in such methods. Provided for is a rapid method of testing for and quantifying ischemia based upon methods of detecting and quantifying the existence of an alteration of the serum protein albumin which occurs following an ischemic event; methods for detecting and quantifying this alteration include evaluating and quantifying the cobalt binding capacity of circulating albumin, analysis and measurement of the ability of serum albumin to bind exogenous cobalt, detection and measurement of the presence of endogenous copper in a purified albumin sample and use of an immunological assay specific to the altered form of serum albumin which occurs following an ischemic event. Also taught by the present invention is the detection and measurement of an ischemic event by measuring albumin N-terminal derivatives that arise following an ischemic event, including truncated albumin species lacking one to four N-terminal amino acids or albumin with an acetylated N-terminal Asp residue.

7449338, Nov 11, 2008

Dec 13, 2002

10/319263

David Bar-Or - Englewood CO, US
Edward Lau - Boulder CO, US
James V. Winkler - Denver CO, US
Gary Fagan - Broomfield CO, US
Hollie Wayment - Elizabeth CO, US

Ischemia Technologies, Inc. - Waltham MA

G01N 33/48

436 63, 436182

The present invention relates to rapid methods for the detection of ischemic states and to kits for use in such methods. Provided for is a rapid method of testing for and quantifying ischemia based upon methods of detecting and quantifying the existence of an alteration of the serum protein albumin which occurs following an ischemic event; methods for detecting and quantifying this alteration include evaluating and quantifying the cobalt binding capacity of circulating albumin, analysis and measurement of the ability of serum albumin to bind exogenous cobalt, detection and measurement of the presence of endogenous copper in a purified albumin sample and use of an immunological assay specific to the altered form of serum albumin which occurs following an ischemic event. Also taught by the present invention is the detection and measurement of an ischemic event by measuring albumin N-terminal derivatives that arise following an ischemic event, including truncated albumin species lacking one to four N-terminal amino acids or albumin with an acetylated N-terminal Asp residue.

8017728, Sep 13, 2011

Nov 2, 2009

12/610508

David Bar-Or - Englewood CO, US
C. Gerald Curtis - Cardiff, GB
Edward Lau - Boulder CO, US
Nagaraja K. R. Rao - Cardiff, GB
James V. Winkler - Denver CO, US
Wannell M. Crook - Castle Rock CO, US

C07K 7/00

530327, 514 215, 514 216, 530328

The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention.

20030060408, Mar 27, 2003

Feb 13, 2002

10/076071

David Bar-Or - Englewood CO, US
C. Curtis - Cardiff, GB
Edward Lau - Boulder CO, US
Nagaraja Rao - Cardiff, GB
James Winkler - Denver CO, US
Wannell Crook - Castle Rock CO, US

A61K038/00
C07K005/00
C07K007/00
C07K016/00
C07K017/00

514/012000, 530/324000

The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention.

20030130185, Jul 10, 2003

Jun 27, 2002

10/186168

David Bar-Or - Englewood CO, US
C. Curtis - Penylan, GB
Edward Lau - Boulder CO, US
Nagaraja Rao - Cardiff, GB
James Winkler - Denver CO, US
Wannell Crook - Castle Rock CO, US

A61K038/10
A61K038/08

514/012000, 514/016000, 514/017000, 514/018000

The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention.